Relay Therapeutics Reports Q3 2026 Financial Results

Relay Therapeutics reported $0 in revenue for the third quarter of 2026, below the FactSet analyst consensus estimate of $1.6 million. The company said it remains focused on its clinical-stage precision medicine pipeline, using computational and experimental technologies to study protein motion and develop treatments for oncology and genetic diseases.